Drug reference
Brolucizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby suppressing endothelial cell proliferation and inhibiting the growth of new vessels and decreasing vascular permeability.
PDF page 1276
Neovascular (wet) age-related macular degeneration (specialist use only) ▶BY INTRAVITREAL INJECTION ▶Adult: Initially 6 mg once a month for the first three doses, to be administered into the affected eye, for continued treatment and subsequent dose intervals— consult product literature, discontinue treatment if no improvement in visual and anatomic outcomes Eye
PDF page 1276
Active intra-ocular inflammation. active or suspected ocular or periocular infection
PDF page 1276
History of myocardial infarction within the past 3 months. history of stroke within the past 3 months. history of transient ischaemic attack within the past 3 months. patients at risk of retinal pigment epithelial tear . poorly controlled glaucoma (do not use while intra-ocular pressure is 30 mmHg or higher). retinal detachment or macular hole (discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular holes develop) CAUTIONS, FURTHER INFORMATION Brolucizumab is given by intravitreal injection by specialists experienced in the management of this condition. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections— patients should be advised to report any signs of infection immediately.
PDF page 1276
Brolucizumab is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1; manufacturer advises to record the brand name and batch number after each administration. l HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2-8°C)—may be stored unopened at room temperature (below 25°C) for up to 24 hours before use; protect from light.
PDF page 1276
▶Common or very common Cataract. eye discomfort. eye disorders. eye inflammation. haemorrhage. hypersensitivity. retinal pigment epithelial tear. skin reactions. vision disorders ▶Uncommon Embolism and thrombosis ▶Frequency not known Myocardial infarction. stroke
PDF page 1276
Manufacturer advises females of childbearing potential to use effective contraception during treatment and for 1 month after treatment.
PDF page 1276
Manufacturer advises avoid unless potential benefit outweighs risk—limited information available.
PDF page 1276
Manufacturer advises avoid during and for 1 month after treatment—no information available.
PDF page 1276
▶Manufacturer advises monitor intra-ocular pressure, perfusion of the optic nerve head, and for signs of ocular infection following injection. ▶Manufacturer advises monitor visual acuity.
PDF page 1276
For further information on administration, consult product literature.
PDF page 1276
There can be variation in the licensing of different medicines containing the same drug. Solution for injection EXCIPIENTS: May contain Polysorbates, sucrose A ▶Beovu (Novartis Pharmaceuticals UK Ltd) Brolucizumab 120 mg per 1 ml Beovu 19.8mg/0.165ml solution for injection pre-filled syringes | 1 pre-filled disposable injection P £816.00 (Hospital only)
PDF page 1276
Initially 6 mg once a month for the first three
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1276
